Friday 30 October 2015

Veterinary Antiseptics Market to Reach US$401.6 mn by 2023, Propelled by Increasing Applications of Antiseptics

Zoetis, Inc., a global animal health company based in New Jersey, recently completed the construction of a 19,000-square-foot, three-story addition to its production site in the Lincoln province of Nebraska. Zoetis introduced its new product, Canine Atopic Dermatitis Immunotherapeutic, which is an antibody therapy for dogs, targeted at reducing atopic dermatitis. The company also introduced a vaccine that cures PEDv, one of the emerging diseases that recently destroyed pig farms in the U.S. The new plant will facilitate the manufacturing of an injectable hormone, Synovex, which promotes weight gain in cattle. According to the authorities at Zoetis, Inc., the product will be ready to be supplied to customers by 2016. 


Last year, Zoetis was engaged in manufacturing a vaccine to cure porcine epidemic diarrhea virus. The company will expand its animal healthcare services in Lincoln and offer reliable animal health products to livestock suppliers, veterinarians, and pet owners. Zoetis, Inc. will be looking to spread its services with new products that are meant to fulfill the changing market needs and assist veterinarians in improving their approach to animal treatment and disease prevention.  

According to Transparency Market Research, the veterinary antiseptics market in Latin America, Asia Pacific, and Rest of the World stood at US$243.0 mn in 2014 and is expected to reach US$401.6 mn by 2023, at a 5.60% CAGR. 

Iodine and Iodophors Sector to Register Highest Growth

Safer and more effective varieties of antiseptics, used for cleaning the skin and wounds, are being adopted by veterinarians and animal care clinics to treat pets. The veterinary antiseptics market in Latin America, Asia Pacific, and Rest of the World is segmented on the basis of product type into iodine and iodophors, alcohol, chlorhexidine, hydrogen peroxide, and others. In veterinary care, iodine and iodophors are the most commonly used antiseptics. The iodine and iodophors sector accounted for the highest market share in 2014 and is expected to maintain its dominant position by 2023. Iodophors also act as a suitable carrier for iodine and provide prolonged and sustained release of antiseptics. Iodophors and iodine are effective against fungi, bacteria, and viruses. 

Chlorhexidine is commonly used as an antiseptic for common domestic animals such as horse, dogs, cats, cows, sheep, and poultry animals. Alcohol is used before vaccination in small animals including dogs, sheep, and cats. Based on species, veterinary antiseptics market in Latin America, Asia Pacific, and Rest of the World is classified into bovine, porcine, ovine, equine, canine, feline, and camelidae. In terms of consumption trends and population analysis, the bovine antiseptics sector accounted for the highest market share in 2014.


Introduction of Advanced Antiseptics to Boost Veterinary Antiseptics Market

Strict regulatory guidelines are expected to restrict the growth of the veterinary antiseptics market. However, the introduction of new veterinary antiseptics by the leading market players is predicted to boost the growth prospects of the market during the forecast period. Some of the leading companies in the veterinary antiseptics market in Latin America, Asia Pacific, and Rest of the World are Bayer AG, Elanco Animal Health, Inc., M.B.D. Marketing (S) Pte Ltd., Merial, Vallée S.A, Zoetis, Inc., Continental Manufacturing Chemist, Inc., Indian Immunologicals Ltd., Merck Animal Health, and Nicosia International.

X-Ray Segment Sees a Bright Future in Global Medical Imaging Equipment Market

The advent of medical imaging equipment has been a boon to the healthcare sector. Starting from the extensive usage of x-rays during World War II and the development of the digital computer, the evolution of ultrasound and magnetic resonance imaging equipment has led to a magnificent growth in diagnostic imaging techniques in the past few years. Growth of the global medical imaging equipment market has given physicians more access to understanding the intensity of diseases, which has led to lowering the rate of morbidity.


X-Ray Segment Emerges as a Leader in Global Medical Imaging Equipment Market

The most popular kind of equipment used in the global medical imaging equipment market is x-ray imaging devices. According to research analysts, the key factor driving the global medical imaging equipment market is the increasing prevalence of respiratory, gastrointestinal, cardiovascular, oral, and genitourinary disorders. Estimates released by the WHO indicate that 80% to 90% adults between the age of 19 to 34 and 60% to 90% of school children will suffer from tooth cavities. Furthermore, the incidence of oral cancer lies between 1-10 cases every 100,000 individuals. These are the two factors that are likely to propel the global x-ray market, thereby making a significant contribution to the global medical imaging equipment market in the coming few years.

Ultrasound to Be the Popular Choice of Devices

The global medical imaging equipment market will also witness a surge in the usage of ultrasound systems as more and more healthcare facilities are adopting them for a wide range of diagnostics. The advantages offered by ultrasound systems, such as utmost safety, real-time image formation, and cost-effectiveness, are making it a popular equipment amongst physicians. Today, these devices are used for scanning and imaging the kidneys, the heart, and other organs, as opposed to using it merely for abdominal imaging purposes.

Some of the key players in the global medical imaging equipment market are Shimadzu Corporation, Philips Healthcare, Siemens Healthcare, Hologic Inc¸ Hitachi Medical Corporation, Genesis Medical Imaging Inc., GE Healthcare, Fujifilm Holdings Corporation, Samsung Medison Co. Ltd., Carestream Health Inc, Toshiba America Medical Systems Inc., and Fonar Corporation.

GE Healthcare and BIOTIC Collaborate for Research and Development for MRI Systems

Innovations and collaborations by leading companies such as GE Healthcare and BIOTIC are going to be the driving factor for this market. Recently, GE Healthcare in Canada announced its plans to work with BIOTIC on a Halifax-based research and development and technology program. This initiative will be directed towards bringing in technological advances to the medical imaging sector for making better diagnoses of diseases related to the prostate, the liver, and the brain.


The venture is aimed at validating the commercial usage of software-powered medical imaging technology as a complementary solution to other MRI systems offered by GE Healthcare. The collaboration will focus on working for GE’s latest acquisition of 3T magnetic resonance imaging (MRI) technology at the QEII Health Sciences Centre. Such partnering and collaborative efforts of the key players in the global medical imaging equipment market are expected to bring in newer technologies that offer better medical intervention for efficient disease management.

Thursday 29 October 2015

How E-prescribing is Helping Save Billions of Dollars in the U.S. Healthcare Industry

E-prescribing constituted a market worth US$250.2 mn in 2015. Business intelligence firm Transparency Market Research estimates that the global e-prescribing market will have a staggering CAGR of 23.5% between 2013 and 2019, by which year the market will have a valuation of US$887.8 mn. These numbers speak volumes about the growing importance of e-prescribing in the healthcare industry. 

The United States has been at the forefront of the E-prescribing market, with states such as Massachusetts adopting e-prescriptions rather extensively. The initial trickle of investments in the electronic healthcare records (EHR) market has now turned into a gushing stream, brought about essentially by the success of early EHR models. The well-spread e-prescribing market in the United States has helped North America attain a dominant position in the global e-prescribing market. Thus, it wouldn’t be wrong to say that the growing adoption of EHR has been a boon for the e-prescribing market. 


Irrespective of Size of Hospital, E-prescribing Systems Help Save Costs

Prescribing errors can prove costly, and in extreme cases, also fatal. The advent of e-prescribing has provided a solution for preventing costly prescription errors. Irrespective of the size of a hospital, reconciling a patient’s history can be a monetary burden. However, this is a burden that’s entirely avoidable. According to the 2014 National Progress Report published by Surescripts, reconciliation of the medication history of a patient can help small hospitals (with about 100 beds) cut 3,331 unnecessary staff hours, and also save US$1.1 mn per year. In the case of very large hospitals (with more than 1,000 beds), savings could amount to US$1,107,045 per year. 

Prior authorization is yet another advantage of e-prescribing and can help pharmacists and physicians save considerable time every week. An earlier study by Surescripts had estimated that first-fill medical adherence could help the United States healthcare industry save as much as US$240 bn over the next decade. 

Impenetrable Security Systems are Need of the Hour in E-prescribing Systems

However, despite all of these advantages, the global e-prescription market will have to contend with issues relating to internet connectivity problems. Since e-prescription services rely on the internet, the adoption of e-prescription tends to be low in rural areas. Unless countries proactively take steps toward improving their healthcare infrastructure, attaining success in the e-prescribing market will remain a distant dream. What further exacerbates this problem is the relatively slow return on investment that accrues from e-prescribing systems. Thus, even before hospitals and healthcare institutions decide on investing in e-prescribing systems, having a robust plan detailing the system’s meaningful use is imperative. 


That’s not all. Most e-prescribing systems are web-based and offer access to multiple users. This naturally brings in concerns about the security of such systems and more importantly, patient-related data. The global e-prescribing industry is in need of more impenetrable security walls with every e-prescribing system, no matter how small or large it is. 

However, although these problems are real, they are certainly not unsurmountable, ensuring that the global e-prescribing market experiences steady growth over coming years. 

Advances in ICP Monitoring Techniques Poised to Fuel Intracranial Pressure Monitors Market


Cerebral monitoring is utilized for managing severe head injuries in human beings. In addition, it is also utilized in the treatment of stroke, subarachnoid hemorrhage, meningitis, hepatic failure, and intracerebral hematoma, and during carotid artery surgery and after neurosurgery. Owing to the rising occurrence of traumatic brain hemorrhages and injuries, intracranial pressure (ICP) monitors are experiencing rapid and cutting-edge technological advancements so that they may establish an efficient treatment regimen. Factors such as the rising number of accidents caused by traffic, the rising geriatric population, and the global expansion of trauma care centers are fuelling the market for intracranial pressure monitors


There are mainly three types of ICP monitors. TMR, a market intelligence company, elaborates upon these three devices in terms of their placement, functions, uses, and limitations.

Intraventricular Catheters: This is the gold standard utilized for measuring the intracranial pressure. An intraventricular catheter is inserted via a right frontal burr hole to the inside of the lateral ventricle. Placement of the intraventricular catheter becomes difficult in case of a compression or displacement of the ventricle. Intraventricular catheters are utilized for the removal of cerebrospinal fluid and for administering drugs such as antibiotics and is attached to either a transducer or a saline manometer. The utilization of intraventricular catheters becomes complicated with any type of infections, but these blockages can be fixed by flushing the entire system and using catheters containing antibiotics.

Intraparenchymal Monitors:  These monitors are inserted in the brain by a small burr hole with a 4mm screw and are considered to be as efficient as intraventricular catheters. These monitors are accompanied by decreased rates of hemorrhages and infections. These are especially useful at times when ventricles are not accessible owing to compression due to raised intracranial pressure. Some of the limitations of intraparenchymal monitors are their inability to be recalibrated, the fact that therapeutic CSF drainage isn’t possible with them, and they are subject to drift if utilized for long periods of time.

Subdural Pressure Transducers: These are extremely simple to place and are the least invasive type of devices. For placing subdural pressure transducers, the dura has to be pierced and the hollow device gets filled up with cerebrospinal fluid. During this filling, the pressure equalizes and the closed tubing filled with fluid passes the pressure into the transducer. With the usage of subdural pressure transducers, the rates of hemorrhages and infections have fallen, but this device isn’t as efficient as intraventricular catheters and intraparenchymal monitors. There can be a number of complications caused by the debris’ misplacement and occlusion. In addition, the removal of cerebrospinal fluid with this device is not possible.


The prominent players operating in the market for intracranial pressure monitors include Haiying Medical, Codman & Shurtleff, Inc., HeadSense Medical, Inc., Medtronic, Inc., Integra LifeSciences Corporation, Spiegelberg GmbH & Co. KG, and Raumedic AG, SOPHYSA, among others.

Major Advancements in Tissue Engineered Skin Substitutes

Tissue engineered skin substitutes are what modern medicine is looking towards for healing damaged skin. These substitutes may be cellular and/or acellular in nature and they act by releasing cytokines and other factors that aid cellular growth around the wounded area. These skin substitutes are usually artificial and are derived from real tissue, either human or non-human. The composition of a tissue engineered skin substitute includes cells and extracellular matrix, which form a premeditated formation of cells and their matrices. The most common areas of use for tissue engineered skin substitutes are in lacerations, vascular ulcers, diabetic ulcers, and burns. 


Biological skin substitutes are considered as the best form of medical intervention while treating the above skin conditions. They are safe, easy to use, and provide the fastest way to heal or repair. The global tissue engineered skin substitute market is exhibiting an incredible CAGR of 17.20% between 2015 and 2023. The market’s recorded value of more than US$0.9 bn in 2014 is expected to grow to US$3.8 bn by 2023.

What’s Making the Tissue Engineered Skin Substitute Market Tick?

Right now, the primary driver of the global tissue engineered skin substitute market is the sheer number of patients that are in need of tissue engineered skin substitutes. This includes patients suffering from vascular ulcers and diabetes, along with the growing geriatric population. Medicine is steadily and surely moving towards the preferable minimally invasive surgeries and surgical tools. This creates the perfect stage for tissue engineered skin substitute in terms of use and R&D. All these factors are proving beneficial for healthcare institutes in Asia Pacific, as they are seen as a more affordable location to undergo surgeries, making the region the largest player in the global medical tourism industry.

The scenario for the global tissue engineered skin substitute market is not all progressive, however. This field of medicine does show a few weaknesses, the most important one being the rather accelerated rate at which diseases could be transferred from one infected tissue sample to a patient. There is a high risk of infection in the post-implementation stage, especially with allogeneic skin substitutes. Another issues the market faces today is the lack of promising reimbursement schemes.

Acellular Skin Tissue Leading Tissue Engineered Skin Substitutes Market

The global tissue engineered skin substitute market is led by substitutes of acellular skin types in terms of the type of tissue engineered. It was the largest segment in the global tissue engineered skin substitute market in 2014 and is also expected to grow at the fastest rate in the near future. The key reasons for the segment’s growth are its low cost, high demand, and easy availability. According to a study, more than half the patients in the U.S. who are undergoing tissue engineered skin substitute surgeries prefer skin surgeries with acellular matrix. 


Prosthetic Skin Could Change the Way we Perceive Artificial Limbs

Scientists are developing new artificial materials that can impart the sense of touch to a prosthetic. This engineered skin will enable a user to feel textures, temperatures, and even the different states of a surface. Stanford University scientists are on the verge of creating this artificial skin, which will allow people wearing prosthetics to feel the various sensations associated with skin.

The top players have dominated the tissue engineered skin substitute market, including Integra LifeSciences Corporation, 3M Health Care, and Medtronic. These companies strive to create the best in biotech and provide us with the latest development in the tissue engineered skin substitute market.

Cell Culture Market Responds to Impressive Progress in Medicine and Healthcare


Cell culture refers to the process of growing cells under controlled conditions, usually outside their natural environment. Even though cell culture techniques were significantly advanced in the 1940s-50s to support research in virology, rapid development of the same in the recent past has been truly remarkable.

The Global cell culture market has been witnessing strong growth in the biopharmaceutical and biotechnology sectors. In 2013, Transparency Market Research pegged the value of the cell culture market at US$6.1 bn, which is projected to rise to US$11.3 bn by 2022, expanding at a 7.10% CAGR during that period. 


Let’s take a look at some of the most recent developments in the field of cell culture. 

3D Cell Growth to Repair Paralyzed Spinal Cord

Researchers at Griffith University have presented a unique technique to grow cells in a 3D format, sans the conventional restrictions of scaffolds and matrices. This new avenue will help advance a therapy that repairs paralyzed spinal cords. Dr James St. John, a research supervisor at Griffith’s Eskitis Institute for Drug Discovery, says that cell growth in a three-dimensional format increases their function and growth prospects, which is especially useful in spinal transplantation repair, wherein cells are transplanted to the site of injury. 

With the help of floating liquid marbles, cells are allowed to freely associate and develop natural structures like they would within the human body. 

Human Trials to Repair Damaged Hearts with Stem Cells

Scientists at the University of Washington (UW) have developed a technique to repair damaged hearts with the help of stem cells and this technique has just received a US$10-mn grant from Seattle-based Washington Research Foundation. This boost will allow scientists to begin the first human trials in a couple of years. 

Dr. Chuck Murry, director of the Institute for Stem Cell and Regenerative Medicine at UW, and his team have shown that stem cells can regenerate damaged heart muscle in guinea pigs, mice, and monkeys.

GE Supplies Bioreactors for Growth of Genetically Modified T-Cells

General Electric Co. has begun supplying bioreactors to drug makers for the growth of genetically modified T-cells in clinical trials. The company’s healthcare division projects that given the increase in the number of patients being treated with engineered cancer-fighting T-cells, drug makers are likely to make at least US$10 bn in sales by 2021. Speaking to Bloomberg in the latter half of October 2015, product leader of GE’s cell therapy technologies unit, Clive Glover, said that the clinical efficacy of experimental cancer immunotherapies will result in higher reimbursement prices, reaching as high as US$500,000 per treatment. 


At the moment, GE Healthcare is the only company supplying bioreactors to developers of engineered T-cells. 

Companies involved in the field of cell culture include Thermo Fisher Scientific, Inc., VWR International, LLC, GE Healthcare, PromoCell GmbH, EMD Millipore, BD Biosciences, Corning Incorporated, Sigma-Aldrich Corporation, and Lonza Group.

Capric Acid Finds Increasing Applications in F&B and Personal Care Industries

A 2011 study by Van Andel Research Institute published in the Journal of Biological Chemistry revealed that decanoic acid – or capric acid – can serve as a regulator of blood sugar levels. Capric acid is a natural, saturated fatty acid and is found in palm kernel oil and coconut oil as well as in the animal fats and milk of certain mammals. The study showed that capric acid may have significant applications in designing safer and better drugs for the treatment of diabetes.

This is just one of the many benefits of capric acid and the market for the same has been on the path of development owing to the rise in consumer awareness. The global capric acid market, according to a report by Transparency Market Research, is estimated to rise from a value of US$1.2 Bn in 2014 to US$1.8 Bn by 2023 at a steady CAGR of 5.0% from 2015 to 2023.


Health Benefits of Capric Acid


Listed below are some of the leading health benefits of capric acid, as found by the American Journal of Clinical Nutrition, Acta Odontologica Scandinavica (a Scandinavian dental journal), the New York Obesity Center, Columbia University, and the Foundation for Alternative and Integrative Medicine.

•    Capric acid, a medium-chain triglyceride, assists in weight and fat loss and may lead to improved energy expenditure
•    Capric acid is broken down and processed in the liver quickly and can therefore be used as a source of energy to power daily workouts
•    Capric acid’s strong antimicrobial and antiviral properties can help combat bacteria, viruses, and the yeast Candida albicans. It can also be used as a denture disinfectant
•    Capric acid helps increase the levels of high-density lipoproteins (HDL) in lactating mothers, which helps protect children from toxins and infections

Keeping these benefits in mind, capric acid finds application in a wide range of end-use industries such as personal care, food and beverage, pharmaceutical, industrial chemicals, plastics, and rubber. 


•    Capric acid is used in the production of esters required to develop perfumes and scents
•    In the personal care industry, capric acid is used in the production of creams and body lotions, given its attributes as an emollient and emulsifier
•    In the food and beverages industry, capric acid is used in the manufacturing of artificial flavors and in wineries, breweries, and meat processing plants
•    It is used to manufacture synthetic rubber
•    It is useful as a plasticizer in the production of a wide range of plastics
•    Capric acid is used to manufacture lubricating grease
•    In the textile industry, capric acid is used for dye manufacturing and textile treatment

Realizing the incredible potential that capric acid possesses, numerous companies have forayed into the market. Some of the leading players competing in the global capric acid market are KLK OLEO, P&G Chemicals, Chemical Associates, Oleocomm Global SDN BHD, PT Bakrie Sumatera Plantations Tbk., IOI Oleochemicals, VVF L.L.C, Temix Oleo Srl, Ecogreen Oleochemicals, and Henan Eastar Chemicals Co., Ltd.

Emulsion Polymers Market: Biobased Emulsion Polymers to Boost Market

High demand for emulsion polymers across the paints and coatings industry, the automobile industry, and building and construction activities has boosted the global emulsion polymers market. Emulsion polymers are primarily used in automotive coatings and architectural coatings. The global emulsion polymers market is projected to expand at a CAGR of 6.1% during the period from 2015 to 2023. The overall market was worth US$32.2 bn in 2014 and is expected to reach a valuation of US$54.9 bn by 2023.

Global Emulsion Polymers Market: Presence of Volatile Organic Compounds Restricting Market

The global emulsion polymers market is expected to be hampered by the stringent regulations related to raw materials such as styrene, butadiene, and urethane. According to the Emulsion Polymers Council, the environmental health and safety aspects of emulsion polymers are quite favorable, with the usage of different small and low-molecular-weight compounds in the manufacturing of high-molecular-weight emulsion polymers with no specific toxicity-related issues. Further, they are supplied in water or solid form to minimize safety concerns.  

Browse Research Report: http://www.transparencymarketresearch.com/emulsion-polymer-market.html

However, the presence of initiators, monomers, and surfactants in the final product leads to traces of volatile organic compounds (VOCs) in the final product. To totally eliminate the presence of VOCs in emulsion polymers, production of biobased emulsion polymers is being stressed upon with technological advancements. The global emulsion polymers market has a huge opportunity to grow with the introduction of biobased emulsion polymers.

Biobased Emulsion Polymers: A New Growth Opportunity for Global Emulsion Polymers Market

The paints and coatings industry has been dominating the overall emulsion polymers market since the past couple of years. Biobased materials such as waxes, gums, polysaccharides, and natural oils are being used for many coating formulations in the industry. Resins based on vegetable oils remain widely popular. Researchers are expanding this technology to include water-based, low-VOC options to manufacture biobased building blocks for polyurethane dispersions, alkyd latex, epoxy ester resins, and oil-modified urethane. Key manufacturers are expanding their portfolio of natural oil-based resins. For example, BASF offers a range of natural oil-based, solvent-free polyols especially designed for PU coatings and adhesives.

Academic research groups are studying potential new materials for the development of biobased coatings. At North Dakota State University, researchers are using derivatives of sucrose-based, low-viscosity fatty esters as raw materials for developing epoxide resins. Further, coating binders are being prepared by esterifying soybean oil with a vinyl ether alcohol. 

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/emulsion-polymer-market.htm

Are Biobased Emulsion Polymers Cost-Effective?

Though biobased emulsion polymers are not affected by the volatility in oil prices, in order to provide an acceptable cost/performance ratio, biobased raw materials need to be available in large quantities. As newer biobased raw materials are not yet produced on a fully commercial scale, their availability is low, which contributes to their increased price. Thus, more refinement is needed before biobased emulsion polymers become mainstream.

Wednesday 28 October 2015

Low-Cost Blood Pump Helps Save Lives when Means for Blood Transfusion are Not Available

In developed countries, patients in an emergency who need blood typically have ready access to it at any given time. However, the same cannot be said of underdeveloped and underserved regions such as Africa, where the number of deaths resulting from blood loss is alarming. What aggravates the situation is that even if blood is available, contamination is a veritable threat.

However, the scenario could soon change with the development of autotransfusion, a process through which a patient’s blood can be circulated back into his or her body. Sisu Global Health, the company behind the product called Hemafuse, wanted to help hospitals by empowering them to address issues related to blood contamination and resultant infections. This process also helps conserve blood, reducing the dependence on donated blood where it isn’t even easily available in the first place.

Blood transfusion machinery can be expensive, making its access limited to hospitals in wealthier countries. Sisu’s CEO Carolyn Yarina says that it’s not as though hospitals in Africa do not have money – they don’t have access to the right technologies. And in cases where such technologies cost thousands of dollars, medical care centers in underserved regions hesitate from investing in them.

The device developed by Sisu is essentially a manually-operated pump, using which blood can be sucked from an abdominal injury or the chest. On pushing down again, the blood flows through a unidirectional valve into a blood bag, where it can be stored for later use. The contraption also comprises a filter that prevents particulate contaminants or clots from passing through.

This innovative product also won Yarina a prize for the best social impact product at the recent SXSW Eco Awards. The young entrepreneur hopes to raise about US$700,000 in a round of seed funding in February 2016.

DuPont Could Consider Consolidation Option as Crop Prices Fall and Fertilizer Output Spikes

Companies engaged in farm-focused businesses are seeking out opportunities for consolidation in the backdrop of the recent downslide in crop prices, which has only been aggravated by an increase in fertilizer output. Last week, the Dow Chemical Co said that it was conducting a fresh review of its farm chemicals and seeds business unit. And now, latest reports suggest that DuPont is also considering this strategy to offset the impact of the unfavorable market forces.

DuPont’s interim CEO, Edward Breen, said this week that the company would do what it takes to provide maximum value to their shareholders. He was responding to questions about whether the company was considering selling its farm unit. Edward took charge in early October 2015 in place on Ellen Kullman, who abruptly vacated office.

There have been rumors suggesting that DuPont is considering taking over Dow’s farm unit. This has left market watchers wondering whether the company has the resources to pull off a deal of such major proportions. Breen did not confirm whether or not his company was willing to either purchase a farm unit or sell its own. As of September 30, 2015, Du Pont’s farm unit represented about 22% of the total revenue filed by the company. However, the company expects its sales to show a dip of about 11% to 12% in 2015.

Breen said that DuPont would soon be reviewing its capital allocation strategy afresh and will also be taking a fresh look at its cost structure. The company is one of the largest players in the agricultural chemicals industry. According to the current financial plans of DuPont, it plans to achieve savings to the tune of US$1.6 billion annually by the end of 2017. However, there is a possibility that the company might have to cut back on this target by at least 10% to 20%, a report in Reuters said.

Tuesday 27 October 2015

Diebold and Citi Testing New ATM that Scans Eyes to Dispense Cash

If a new technology being tested by Citibank and Diebold is successful, customers of the former could soon be able to enjoy cardless cash withdrawals at ATMs. Diebold, a company that specializes in ATM design and marketing, has come up with a novel technology that simply scans a person’s eyes to authenticate transaction requests. If this idea does take off as expected, it could well herald a whole new way of ATM banking, which would essentially make cards obsolete.

The new machine, called the ‘Irving model’, is slated to be unveiled at a trade show for financial services providers in New York this week, even as Citigroup is conducting tests to assess the viability of the machine in the same city. That biometrics is becoming the norm is becoming evident with such new initiatives.

This ATM banking concept also brings into focus the growing importance of biometrics in our everyday lives – from banking to vehicle and home automation. At this point, though, Citi is trying to assess if consumers would be willing to accept this technology, not just in the U.S. but also across other major global markets.

The machine’s design makes a conscious move away from touchpad-based interaction seen at conventional ATMs. Instead of a boxy screen, the user’s interface will be his or her own smartphone. Once a customer has signed in through a mobile phone or tablet, their account balance will be displayed on their own handheld device. The customer will then determine the amount to be withdrawn and key in into mobile or tablet. The ATM machine will then authenticate the transaction by scanning the customer’s iris and verify the identity. Once the identity is verified, the machine will automatically dispense the requested amount of cash.

While that might sound like a complex process, Diebold says that the entire transaction takes no more than 10 seconds. Using the optimal camera for iris scanning is vital to the success of this technology, and Diebold says that they are working with different vendors to attain the perfect solution.

Monday 26 October 2015

eDiscovery Market to Witness Significant Growth with Increasing Usage of Mobile Devices

eDiscovery solutions are being increasingly adopted by governments and regulatory agencies. Increasing volume of electronically stored information (ESI) and growing usage of social media in organizations has increased the demand for on-premise as well as off-premise eDiscovery software solutions. With legal work continuing to move in-house at corporations, internal experts are focusing on cyber security and eDiscovery solutions. The global eDiscovery market is estimated to expand at a CAGR of 16.2% during the period between 2014 and 2020. The global eDiscovery market was worth US$5.5 bn in 2013.

eDiscovery Solutions: Steep Costs Restrain Organizations from Investing in eDiscovery
It is no secret that eDiscovery solutions are costly. In fact, it has been estimated that eDiscovery costs alone account for around 90% of litigation costs. The high cost associated with eDiscovery processes is expected to hinder the growth of the global eDiscovery market. Investing in eDiscovery becomes more expensive if organizations do not take some preparatory steps. To minimize exposure to steep eDiscovery costs, following are some of the proactive steps firms need to take:

Record Retention Policy: In a year, the total amount of data received or generated by the average office worker is huge. Though the cost of hard drives has relatively gone down and allowed companies to buy more storage space, this is not the ideal way out. Organizations need to devise a record retention policy that determines when documents can and should be deleted.

A Catalogue of Historical Organizational Charts: A good organizational chart helps immensely during legal investigations. It has been pointed out by courts that organizational charts are usually neglected while analyzing discovery failures. Using and updating an organizational chart makes it easier for companies during legal hassles.

Data Map: A data map is of utmost importance to keep a track of all the different locations where ESI has been stored. An ideal data map would reveal the various network storage location, computers, handhelds, and cloud servers that the organization uses for its business purposes. Further, a data map would also note which of those sources come under automatic deletion protocols.

Legal Hold Plan: By designing implementation and monitoring procedures, organizations can streamline the time-sensitive process of implementing a legal hold.

There is no foolproof way to avoid liability when it comes to electronic data. However, a good eDiscovery strategy helps in this regard immensely. In the near future, the growing usage of mobile and handheld devices is anticipated to instigate the next eDiscovery wave. Civil litigations and regulatory audits will be witnessing a radical shift with the increased amount of digital data and introduction of advanced eDiscovery tools. With the development of new eDiscovery tools, the overall eDiscovery process is evolving rapidly. Organizations need to update their eDiscovery strategies accordingly.

Context Rich Systems: Leading Strategic Technology Trend in 2015


Context rich systems are the latest rage in the global IT industry. Gartner Inc., has included this technology in the list of top ten strategic technology trends for 2015. The publication predicts an immense rise of the trend of context rich systems, which are said to have the ability to understand their users and make appropriate responses.



Rising Requirement for Adaptive and Reactive Technologies Boosts Context Rich Systems Market

Transparency Market Research (TMR), a market intelligence and research firm, has recently published a market study on the global context rich systems market. According to the report, the trend of context-rich systems is inlined with the rising demand for more adaptive as well as reactive technology. The customization of the experience is another reason, driving the demand for context rich systems.

The report states that the global market for context rich systems market stood at US$1.7 bn in 2014. Expanding at a CAGR of 15.90% between 2015 and 2022, the market is predicted to reach US$5.8 bn by the end of 2022.

Browse Research Report: http://www.transparencymarketresearch.com/context-rich-systems-market.html

The increasing focus on user experience has boosted the worldwide context rich systems market to a high level. The rising penetration of mobile phones, the augmenting demand for laptops, smartphones, and tablets from consumers across the world, and increasing expenditure on IT infrastructure are also some of the significant reasons for the exceptional growth of this market.

Though the market looks thriving at once; however, concerns over privacy and data security and unavailability of appropriate standards are likely to hamper the development. Upselling and cross selling, on the other hand, are expected to benefit market players at all levels in the near future.

North America or Asia Pacific – Identifying the Future Market Leader

North America is the leading regional market for context rich systems. In 2014, it emerged as the biggest revenue generator, accounting for around 35% in the global context rich systems market.

The huge demand for context rich systems from B2B companies and the presence of many of the leading market players such as Apple (iPhone series), Research in Motion (Blackberry), and Google (Motorola and Android) in this region are the two main reasons for the dominance of North America.


Europe also boasts of the presence of major market participants and, owing to this, it has acquired the second position in the global market. However, it is the Asia Pacific region, which has taken the global market to storm. Analysts have projected the context rich systems market in Asia Pacific to report the fastest growth during the period from 2015 to 2022 and achieve a significant chunk of the overall market share.

The economic development of the emerging Asian nations, together with the rising investment for R&D activities in the area of context rich systems, is driving this regional market extensively.

Flytxt, IGATE Corp., Amazon.com Inc., DS-IQ Inc., Microsoft Corp., Apple Inc., Baidu, Google Inc., Facebook Inc., and InMobi are the major players operating in the global context rich systems market.

Lava Dials up Investments with Capacity Expansion in South and North India

Mobile handset vendor Lava International Ltd. said this week that it is deepening its investments in India. To this end, Lava will undertake manufacturing capacity expansion in the country; the capacity addition will enable the company to manufacture as many as 18 million mobile handsets a month. The new capacity additions are expected to come into effect in a phased manner over the next six years, said recent media reports in India. By 2021, Lava’s fresh investments will amount to US$338 mn (as per exchange rates on October 26, 2015).

With many of its rivals already focusing on the future, Lava hopes that its new facilities in Tirupati and Noida will help it compete head-to-head in an increasingly dynamic mobile handset manufacturing market in India.

Sanjeev Agarwal, Lava’s chief manufacturing officer, said that the company aims to have its two plants in Tirupati and Noida operational by the end of 2017. However, the better part of Lava’s investments will be channeled into its Noida manufacturing facility. The sprawling manufacturing plant, spread over an area of 100 acres, will be located on the crucial Noida expressway. The facility will not merely manufacture handsets, but will also house a hardware R&D plant with a sizeable investment of INR 500 crore. Lava’s current hardware R&D facility is located in Shenzhen, China, whereas its software research team sits out of Bengaluru, India.

About INR 500 crore is being pumped into Lava’s Tirupati manufacturing plant, which could potentially cater to demand stemming from the Southern states in India. The manufacturing plant in Tirupati will be crucial in that it will also house units for other cellphone vendors such as Karbonn, Micromax, and Celkon. An appreciable 6,400 jobs are expected to be generated once both the planned facilities are operational.

Besides achieving economies of scale, Lava also hopes that its new investments will receive backing from respective governments and earn subsidies and VAT benefits.

Wednesday 21 October 2015

Will the Trans-Pacific Partnership Deprive Poorer Countries of Biological Drugs?

The 12 Pacific Rim nations that had been engaged in long-drawn negotiations to effect the Trans-Pacific Partnership (TPP) finally reached a consensus in early October 2015. The TPP—when it is officially effected in early 2016—will be the largest free-trade agreement to date and will cover a third of all global trade.

Although the deal is aimed at reducing trade barriers between the partners and to create a common intellectual property framework, it has received criticism for being secretive and skewed in favor of the wealthier nations. And now, there are added concerns that the TPP could also deprive the poorer nations that are a part of this agreement from gaining timely and affordable access to biological drugs.


Why are Biological Drugs so Important?

The high economic burden of chronic non-communicable disorders has prompted both public healthcare agencies and private pharmaceutical companies to fire the engines in developing biological drugs. The World Health Organization (WHO) states that about 60% of the 56.4 million deaths worldwide in 2001 resulted from chronic diseases. Chronic diseases alone accounted for 46% of the global disease burden, and this figure is expected to rise considerably to 57% by 2020, the WHO says. 

The rising incidence of chronic diseases worldwide will lead to an intensified focus on developing biological drugs thanks to their advantages over non-biological drugs. Transparency Market Research says in its latest report that the growing burden of chronic diseases will largely stimulate growth in the global biological drugs market, which is projected to exceed US$287.1 bn by 2020. However, the high cost of biological drugs is the greatest impediment to the growth of the market. 

How will the TPP Prevent Poorer Nations from Gaining Access to Biological Drugs?

Biological drug development calls for massive amounts of time, money, and expertise. The Brookings Institution, a not-for-profit organization that conducts independent research on policy decisions, states that the cost of making structurally complex biological drugs is about 22 times more than comparable small-molecule drugs. The high cost of developing biologics naturally adds to their market price. This has resulted in a parallel ‘biosimilars’ market. 
As the name suggests, biosimilars are more affordable ‘copies’ of the generic drugs and are thus more readily purchased by consumers. Understandably, companies that spend several years and millions of dollars in developing biological drugs have been lobbying hard to prevent competitors from replicating their formulas and developing counterfeit products. This lobbying has paid off in several countries where governments now grant data exclusivity to manufacturers of biological drugs. This data exclusivity prevents drug regulation authorities from approving biosimilars for a set number of years. In the United States, for instance, biologics enjoy a 12-year data exclusivity period. 

However, this is also where disparate data exclusivity timeframes come into the picture. Poorer countries such as Brunei, for example, have no data exclusivity period at all. To ensure that the TPP doesn’t compromise the stronghold of large U.S.-based pharmaceutical companies, the U.S. has been pushing hard to have every country in the TPP agreement sign a biologics data exclusivity clause. All parties concerned have finally agreed to sign a data exclusivity clause, which reportedly ranges between five to eight years. 

Healthcare experts and activists feel that data exclusivity will delay the introduction of biosimilars into several nations. The ramifications of this will be more severe in poorer nations where patients simply wouldn’t be able to afford expensive biological drugs and will lose out on effective therapies. Thus, the already pressing concern of prohibitively expensive biological drugs will be exacerbated by the Trans-Pacific Partnership.


Thus, unless a fair biologics data exclusivity period is granted to poorer countries who are a part of the TPP, patients here are at risk of missing out on life-saving medicines. 

Rising Incidence of Injuries Propels Orthopedic Trauma Fixation Devices Market

The orthopedic trauma fixation devices market has witnessed robust growth in recent times. According to a research report, published by Transparency Market Research (TMR), in 2013, the global market for orthopedic trauma fixation devices stood at around US$5 bn, and reported a slight increase in market value in 2014, reaching US$6.1 bn. Analysts at TMR estimate this market to rise at a CAGR of 7.20% during the period from 2014 to 2020 and attain a value of US$9.3 bn by the end of 2020.


The rapid increase in accidences, including sports injuries, has fueled the global orthopedic trauma fixation devices market to a significant extent. The usage of advanced technologies resulting in positive clinical outcome is also triggering the uptake of orthopedic trauma fixation devices. Apart from this, rising disposable incomes have encouraged customers to increase expenditure on healthcare, which is also a major reason for the growth of this global market.

On the other hand, the high cost associated with surgeries and the lack of proper knowledge regarding health insurance in emerging economies are creating severe challenges for the worldwide orthopedic trauma fixation devices market. However, analysts predict that the dearth of alternative treatment will continue to boost the market in the coming future.

The global market for orthopedic trauma fixation devices is analyzed on the basis of the type of fixators, composition, and the regional distribution of this market.

Internal fixators and external fixators are the two main segments of this market based on the type of fixators. The internal fixator market is further segmented into the markets for intramedullary nails, plate and screw systems, and intramedullary screws. Based on the composition, metallic and bioabsorbable fixators are the key segments and regionally, North America, Europe, Asia Pacific, and the Rest of the World are the major markets for orthopedic trauma fixation devices. Here is a snapshot of the current and historical performances of every segment of this market:

The market for internal fixators leads the global orthopedic trauma fixation devices market and is likely to expand at CAGR of around 6.80% during the period from 2014 to 2020.

The plate and screw systems market dominates the internal fixators segment and is expected to report a CAGR of around 7.10% between 2014 and 2020.

The bioabsorbable fixators market is projected to rise at a CAGR of around 8.40% from 2014 to 2020.

North America occupies the leading position in the global trauma fixation devices market. However, Asia Pacific is estimated to report the fastest growth over the 2014-2020 period.


The major companies operating in the global market for orthopedic trauma fixation devices are Johnson & Johnson Services Inc., Wright Medical Technology Inc., Tornier Inc., Braun Melsungen AG, CONMED, Orthofix Holding Inc., Smith & Nephew, Arthrex Inc., Medtronic Inc., Stryker Corp., Integra LifeSciences Holdings Corp., and Zimmer Holdings Inc. Among these, Johnson & Johnson leads the worldwide market with a share of 47.3%.

Recent Research Studies Encouraging Growth of Global Circulating Tumor Cells Prognostic Technologies Market

Growing prevalence of cancer across the world along with the development of therapeutic monitoring is propelling the growth of the global circulating tumor cells (CTCs) prognostic technologies market. The global CTCs prognostic technologies market is expected to take a leap at a CAGR of 26.30% during the period between 2014 and 2020. The overall CTCs prognostic technologies market was worth US$0.43 bn in 2013 and is projected to be valued at US$2.16 bn by 2020. North America is the leading market for CTCs prognostic technologies owing to the increased prevalence of cancer in countries such as the U.S. and the high adoption rate for advanced prognostic technologies. 


Early Detection of CTCs in Prostate Cancer Patients Undergoing Radiation Therapy Helps in Clinical Decision-Making

The global CTCs prognostic technologies market for prostate cancer is likely to register the fastest growth at a CAGR of 25.20% during the period from 2014 to 2020. In 2013, the demand for CTCs prognostic technologies for prostate cancer was the highest. Latest advancements in prognostic technologies have aided the growth of the global CTCs prognostic technologies market. 

According to Nature, a leading weekly international scientific journal, an estimated 233,000 new cases of prostate cancer were diagnosed in the U.S. in 2014. A recent publication in the journal suggests that the presence of CTCs in prostate cancer patients undergoing radiation therapy may be indicative of the disseminated disease. The study detects the presence of CTCs in the blood of prostate cancer patients with the help of CellSearch System (CSS), which has been approved by the U.S. Food and Drug Administration. Assessment of CTCs in the blood of prostate cancer patients undergoing adjuvant and salvage radiation therapy can be helpful in clinical decision-making. Further it also helps evaluating the efficacy of radiation therapy versus other systemic treatments.


Researchers Develop Acoustic System to Detect CTCs

Cancer cells usually migrate from their original locations by circulating through the blood stream and forming new tumors elsewhere in the body. The detection of circulating tumor cells (CTCs) is necessary for the doctors to analyze whether a patient’s tumor will metastasize or how the patient is responding to the treatment. However, detecting these cells is challenging as there might be only one to 10 such cells in a 1 millimeter sample of a patient’s blood. A team of engineers from the Massachusetts Institute of Technology, Carnegie Melon University, and Penn State University have found out a new way to isolate CTCs from patient blood samples. The researchers have developed a new acoustic system that can isolate at least 83% of the cancer cells from samples. The new cell-sorting device can separate CTCs from blood cells by using sound waves which would enable many fundamental research studies and clinical applications. 

Appeal of Young Look among Baby Boomers Drives Anti-aging Market

Baby boomers advancing towards retirement are determined to defy the aging process. Every year, they spend millions of dollars on face-lifts, wrinkle creams, and workout regimens in pursuit of their ‘forever young’ mindset, which cosmetic product manufacturers, cosmetic surgeons, and entrepreneurs are eager to capitalize on. Baby boomers constitute a 70-million-strong group for legions of businesses to target.
The Boomers, who grew up in America’s postwar prosperity, are regarded as a more privileged generation than any before them. From top-of-the-line incomes to widespread government subsidies for post-war education and housing, they were the wealthiest and the most physically fit generation. 


Nevertheless, often criticized for rejection of traditional values and their characterization of excessive consumerism, the boomers were a disparate lot.  The demographic group that embraced fashion in every department, self-care and looks being foremost to keep with their modernist mindset.

Health Issues and Aging Now upon Baby Boomers 

With baby boomers already in their 60s, aging and health problems have already struck upon individuals of the age group. Their impending retirement from the workforce has also weighed heavy on this demographic. Nonetheless, in true baby boomer style, this group will probably approach the state in a new way. Regardless of aging, baby boomers are emphatic upon staying in their homes and communities and not in assisted-living settings, which necessitates the usage of anti-aging products and services. 

Hence, the desire of the baby boomer generation to retain their youth is expected to be a major revenue generation channel for the anti-aging market in the coming years. As a result, the anti-aging market, which amounted to a value of US$122.3 bn in 2013, is slated to shoot up to US$191.7 bn by 2019, says a recent market study by Transparency Market Research (TMR).


TMR analysts have presented the views of the vendors of anti-aging products and the medical community about the use of anti-aging products and services:

1) Anti-aging enthusiasts assert that the use of recognized deficit-correcting treatments and oral supplements helps in the near term as well as long run with increased life expectancy. On the contrary, critics as well as the most of the medical fraternity contend that anti-aging interventions do not give desired results and may also be harmful. 

2) Mainstream organizations such as the National Institute on Aging advise consumers to be wary about possible scams due to false promises labeled on anti-aging products. Rather, the institute contends aging to be normal, which cannot be slowed or reversed with the use of pills or treatments that claim to lead to endless youth.

3) North America is the dominant market for anti-aging products and services due to a large concentration of the baby boomer population. Baby boomers constitute 44% of the U.S. population and account for 70% of the disposable income in the country, thereby accounting for a large total expenditure on aesthetics enhancing and anti-aging products.

Tuesday 20 October 2015

Apple Music has 6.5 million paying subscribers in Three Months of Launch, says CEO Tim Cook

In just over three months of its launch, Apple Music claims to have 6.5 million paying subscribers on board. And about 8.5 million potential users are opting for the free three-month trial of the music streaming service, which was launched by the tech giant on June 30, 2015. The service, which features playlists curated by leading DJs and musicians, also has a live round-the-clock radio station. When it launched, the service was in direct competition with as Spotify, the leader in the music streaming space with 20 million paying subscribers.

During interactions with members of the press at the Wall Street Journal technology conference, Apple CEO Tim Cook said that Music’s strong point was that the playlists were curated by humans, and the service carried the ability to recommend new tunes on a per-user basis.

Besides Apple Music, Cook also spoke extensively on other hot topics such as the future of autonomous cars, the much-awaited launch of Apple TV, and data privacy concerns. Cook, however, could not be made to divulge much about sales of the Apple Watch and the company’s rumored plans of launching an entire range of next-generation hardware. He also stepped around specific questions pertaining to the Apple Car, but did say that the auto industry was at an “inflection point” and would go through a change that was not merely of an evolutionary nature.

Anticipation around the launch of the upgraded version of Apple TV is building up rapidly, and Cook confirmed during the interview that Apple will start accepting orders for the updated version starting Monday, October 26. Last month, the company unveiled an updated version of the Apple TV video streaming box, which now brings features such as an app store to its consumers. A touch-enabled remote control is yet another distinguishing feature of the updated version of the Apple TV.

Monday 19 October 2015

5 Reasons Why Water Utilities in Global Smart Water Management Market are Apprehensive

The global smart water management market, similar to other markets such as tourism, manufacturing, insurance, and energy, is projected to benefit greatly from the networking benefits of the Internet of Things (IoT). However, the other markets have already witnessed significant deployment of the Internet of Things, while the global smart water management market is still lagging behind.

The global smart water management market is at a nascent stage and though characterized by high level of interest in smart technologies, it suffers from low deployment rates. Let’s look at why water utilities around the world are still apprehensive about adopting smart solutions in the field of water management.

#1 – Lack of Capital Requirements
Water utilities aiming to deploy smart water management solutions will need to invest significantly in order to replace the aging infrastructure. However, cost is one of the key concerns for water utilities in the global smart water management market. ROI gains in the global smart water management market take a period of more than a decade, making it less attractive for the majority of water utilities in the short term.


#2 – Lack of Long-term Evidence of Reliability
The security and reliability of smart water management solutions is not established yet, as there is little history available about the implementation of these solutions. Hence, water utilities are still relying on conservative methods for water management. In addition to this, water utilities are generally not early adopters of new processes or technology. At present, there are a very limited number of case studies that show successful deployment of smart water management solutions.

#3 – Limited Availability of Smart Water Solutions
The limited availability of smart water management solutions is another key concern for water utilities. Like the concerns with the reliability of these systems, only sustained usage will solve this issue, as rising demand will lead to rising production as well as a fall in prices.

#4 – Lack of Innovation due to Funding Shortage
The overall lack of incentives to drive innovation in utilities is also challenging the adoption of smart water grid technology. Investment in a new technology would outweigh the costs for those paying in the long run. Nevertheless, the lack of sufficient capital investment is suppressing technological advancement in the global smart water management market.


#5 – Cyber Security Issues
Data security is one of the top concerns related not only to smart water meters, but also smart electric meters. As water meters are located in an open area, a cyberattack affecting service providers and users in the network can greatly impact services in the smart grid. These cyber security-related issues are further suppressing the adoption of smart water management technologies in worldwide.

These were the top 5 factors that are restraining the deployment of smart water management technologies around the world. Nevertheless, with growing awareness, advancement in technology, and government backing, the global smart water management market will gradually grow in the foreseeable future. In addition to this, the growing need for mapping water resources and to reduce water loss due to leaks will further drive the global smart water management market.

New Energy-efficient Product Innovations Featuring Embedded Intelligence to Drive Medium and High Power Motors Market

The increasing cost of electricity and rigid regulations on electricity consumption have pushed industrial users to prefer energy-efficient machinery and electric motors in order to lower their operational costs. A large number of manufacturers have brought in new innovations and refinements in medium and high power electric motors that have fuelled the market for medium and high power electric motors. This is why the market is expected to reach US$69.9 bn by 2019.

TMR, a market intelligence company, has profiled the key manufacturers operating in this market, along with presenting their new product advancements. The prime application areas of these motors have also been elaborated in order to acquaint users with informational and up-to-date information.

Browse Research Report: http://www.transparencymarketresearch.com/low-medium-voltage-motors.html

Regal Beloit: This company is a leading manufacturer of electric motors and is headquartered at Beloit, Wisconsin. Regal has sales, service, and manufacturing facilities in Canada, the U.S., Asia, and Europe. Being amongst the biggest electric motor manufacturers, Genteq brand’s brushless DC electric motors are made by Regal and are utilized in a number of variable-speed residential HVAC devices within the U.S.

DEC Star: This new blower and motor system utilized in HVAC equipment has been recently launched by Genteq, a Regal brand. The full form of DEC is dual-efficiency configuration and it is used in applications such as fan coil units, furnaces, and packaging units, among others.

LEESON Platinum e PMAC motors: Regal has introduced these motors with a permanent magnetic alternating current (PMAC) motor. They are used in air-conditioning and ventilation retrofits, blowers, fans, and pumps.

Asmo Co Ltd: This company manufactures, sells, and develops motor systems for office automation machines and automobiles. Various environmentally oriented products are provided by this company, such as electronic throttle valve control, electric power steering, variable nozzle turbo, motors for EGR systems, cooling fan motors, and electric water pumps, among others. This company presently manufactures electric motors that are utilized primarily in car air-conditioners, car ventilation systems, and power window systems.

Wiper Motors and Link: These are manufactured by Asmo and are crucial parts of a car wiper system. The motor helps move the links, thus resulting in the swiping movements of wiper movement. Wipers that are properly operating are very important for the proper cleaning of the car windshield.

Power Window Motor: The company has launched intelligent, reliable, and quiet motors that are used in window systems within car doors. A number of car manufacturers use motors made by Asmo in order to provide a pleasant and comfortable drive to their customers.

Browse Press Release: http://www.transparencymarketresearch.com/pressrelease/low-medium-voltage-motors.htm

Baldor Electric Company: This company is a leader in designing, manufacturing, and marketing mechanical power transmission product drives, industrial electric motors, and generator sets.

AC Brushless Servo N-Series Motors: These motors are utilized within the world’s most demanding and fastest applications such as robotics, capping machines, and packaging, among others.

Shaft Grounding Motors:  These motors comprise the Baldor internal shaft grounding brush and are utilized within applications having variable speed primarily within HVAC and pump industries.